跳至主要内容
临床试验/NCT00373087
NCT00373087已完成4 期

Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease

Assistance Publique - Hôpitaux de Paris1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
60
试验地点
1
主要终点
L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test

研究概览

简要总结

Entacapone is an antiparkinsonian drug which block L-dopa metabolism, inhibiting the C-O-methyltransferase (COMT) enzyme. There is an individual variability of the COMT activity determined by a genetic polymorphism. The aim of this study is to investigate whether the genetic variability influences entacapone efficacy in Parkinson's disease.

详细描述

COMT protein is dependent of a single autosomal locus with two co-dominant alleles with a high activity (allele H) and a low activity (allele L) form of the enzyme. L and H allele frequency in the Caucasian population is around 50%. This is a monocentric randomized blinded cross-over study comparing acute challenge of L-dopa + placebo versus L-dopa + 200 mg entacapone, in Parkinson's disease patients with HH and LL genotypes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
30 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Parkinson's disease
  • wearing off

排除标准

  • atypical parkinsonism
  • neuroleptic use

研究组 & 干预措施

L-dopa + entacapone

Active Comparator

L-dopa + entacapone

干预措施: entacapone (Drug)

L dopa / placebo

Experimental

L dopa / placebo

干预措施: l dopa versus placebo (Drug)

结局指标

主要结局

L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test

时间窗: during the hospitalization in 24 hours

L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test

次要结局

  • Pharmacokinetics of L-dopa and its metabolites(at the end of the study during the last hospitalization)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

COMT Polymorphism and Entacapone Efficacy | 临床试验